Company: RCUS
Filing Date: 2025-02-18
Form Type: 8-K
Source: 0001193125-25-028110
Chunk: 0

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition.

On February 18, 2025, Arcus Biosciences, Inc. (the “ Company”) reported that, as of December 31, 2024, it had approximately $992 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and marketable securities balance set forth above reflects its preliminary estimate with respect to such information, based on information currently available to management, and may vary from its actual financial position as of December 31, 2024. Further, this preliminary estimate is not a comprehensive statement or estimate of its financial results or financial condition as of December 31, 2024.